Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, Vallier AL, Hiller L, Dunn JA, Bowden SJ, Hickish T, McAdam K, Houston S, Irwin MJ, Pharoah PD, Brenton JD, Walton NA, Earl HM, Caldas C. Ali HR, et al. Among authors: iddawela m. Breast Cancer Res. 2016 Feb 16;18(1):21. doi: 10.1186/s13058-016-0682-8. Breast Cancer Res. 2016. PMID: 26882907 Free PMC article. Clinical Trial.
Epirubicin as adjuvant therapy in breast cancer.
Earl H, Iddawela M. Earl H, et al. Among authors: iddawela m. Expert Rev Anticancer Ther. 2004 Apr;4(2):189-95. doi: 10.1586/14737140.4.2.189. Expert Rev Anticancer Ther. 2004. PMID: 15056049 Review.
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, Houston S, Hickish T, Skene A, Chan S, Dean S, Ritchie D, Laing R, Harries M, Gallagher C, Wishart G, Dunn J, Provenzano E, Caldas C; Neo-tAnGo Investigators. Earl HM, et al. Among authors: iddawela m. Lancet Oncol. 2014 Feb;15(2):201-12. doi: 10.1016/S1470-2045(13)70554-0. Epub 2013 Dec 19. Lancet Oncol. 2014. PMID: 24360787 Free article. Clinical Trial.
Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.
Gounaris I, Provenzano E, Vallier AL, Hiller L, Iddawela M, Hilborne S, Taylor K, Britton P, Earl HM, Sinnatamby R. Gounaris I, et al. Among authors: iddawela m. Breast Cancer Res Treat. 2011 Jun;127(2):459-69. doi: 10.1007/s10549-011-1454-x. Epub 2011 Mar 25. Breast Cancer Res Treat. 2011. PMID: 21437610
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C. Sayal K, et al. Among authors: iddawela m. Int J Gynecol Cancer. 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. Int J Gynecol Cancer. 2015. PMID: 25962114 Free PMC article. Clinical Trial.
24 results